Oculis AGM Backs All Proposals, Adds Veteran Biotech CFO to Board and Expands Capital Flexibility

Oculis Holding ( (OCS) ) has issued an update.

On May 13, 2026, Oculis Holding AG held its 2026 Annual General Meeting in Zug, Switzerland, where shareholders approved all agenda items, including the 2025 annual and consolidated financial statements, despite a standalone statutory loss of CHF 33.67 million for 2025 and an accumulated balance sheet loss of CHF 80.25 million, which will be carried forward. The meeting also confirmed the discharge of the Board and Executive Committee for 2025, re-elected all incumbent directors, appointed Gregory D. Perry to the Board and to the Compensation Committee, and maintained PricewaterhouseCoopers as statutory auditor and Blum & Partner as independent proxy.

Shareholders approved detailed compensation caps for non-executive directors and the Executive Committee, endorsed the 2025 compensation report in a non-binding vote, and authorized a capital band and new conditional share capital for employee and similar incentive plans. Oculis simultaneously updated its Articles of Association, increasing registered shares to 62,041,776 to reflect equity award settlements and EBAC warrant exercises through March 31, 2026, and the Board authorized issuance of 5,750,400 additional treasury shares for potential use in its at-the-market and other offerings, which will bring total registered shares to 67,792,176 and leave the company holding about 9.15% of its own stock in treasury, underscoring continued emphasis on capital flexibility and access to U.S. markets.

The election of veteran biotech finance executive Gregory D. Perry, who previously served as CFO of Merus N.V. through its acquisition by Genmab and held senior roles at several U.S. and European life sciences companies, strengthens Oculis’s governance and capital markets expertise. The Board highlighted his experience guiding European-based biotechs under U.S. capital markets standards, particularly Nasdaq, as strategically important as Oculis pursues long-term shareholder value and advances its late-stage ophthalmic and neuro-ophthalmic pipeline.

The most recent analyst rating on (OCS) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Oculis Holding stock, see the OCS Stock Forecast page.

Spark’s Take on OCS Stock

According to Spark, TipRanks’ AI Analyst, OCS is a Neutral.

OCS scores as a higher-risk biotech: strong recent price momentum lifts the score, but it is outweighed by weak financial performance driven by large ongoing losses and sustained free-cash-flow burn. The low-debt balance sheet is a meaningful stabilizer, while valuation remains challenged due to negative earnings and no dividend support.

To see Spark’s full report on OCS stock, click here.

More about Oculis Holding

Oculis Holding AG is a global biopharmaceutical company listed on Nasdaq and XICE that focuses on breakthrough therapies for significant unmet medical needs in neuro-ophthalmology and ophthalmology. Its late-stage pipeline includes OCS-01, a topical eye drop in pivotal registration studies for diabetic macular edema, Licaminlimab, a genotype-guided anti-TNFα eye drop in a registrational trial for dry eye disease, and Privosegtor, a neuroprotective candidate in the PIONEER program for optic neuropathies such as optic neuritis and non-arteritic anterior ischemic optic neuropathy. Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team and backed by international healthcare investors.

Average Trading Volume: 373,793

Technical Sentiment Signal: Buy

Current Market Cap: $1.74B

For detailed information about OCS stock, go to TipRanks’ Stock Analysis page.